MYC and adenocarcinoma: Hence, the signature “stromatype” of the aggressive adenocarcinomas induced by sustained co-activity of KRasG12D and Myc is an immediate, instructed consequence of Myc activation, not an indirect or generic tissue reaction to disruption by the expanding tumor in its midst.